Amylyx Pharmaceuticals (AMLX) Operating Expenses (2021 - 2026)

Amylyx Pharmaceuticals' Operating Expenses history runs 6 years deep, the most recent figure standing at $43.8 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 15.81% year-over-year to $43.8 million; the TTM figure through Mar 2026 stood at $159.3 million (down 30.49% YoY), while the FY2025 annual figure was $153.3 million, down 61.88% from the prior year.
• Operating Expenses was $43.8 million for Q1 2026 at Amylyx Pharmaceuticals, up from $36.6 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $210.8 million in Q1 2024 to a low of $36.0 million in Q3 2025.
• Historically, Operating Expenses has averaged $68.5 million across 5 years, with a median of $55.0 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Operating Expenses jumped 271.57% in 2022, then sank 82.06% in 2025.
• A 5-year view of Operating Expenses shows it stood at $66.5 million in 2022, then jumped by 60.23% to $106.5 million in 2023, then slumped by 62.46% to $40.0 million in 2024, then decreased by 8.46% to $36.6 million in 2025, then grew by 19.6% to $43.8 million in 2026.
• The last three Operating Expenses figures came in at $43.8 million (Q1 2026), $36.6 million (Q4 2025), and $36.0 million (Q3 2025), per Business Quant data.